Published in Arch Roum Pathol Exp Microbiol on March 24, 1976
Hemin-deficient mutants of Escherichia coli K-12. J Bacteriol (1968) 2.69
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol (1999) 1.35
Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol (1999) 1.26
Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol (1999) 1.15
Repair of single-stranded DNA nicks, gaps, and loops in mammalian cells. Mol Cell Biol (1987) 1.13
Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol (2001) 1.10
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol (1999) 1.09
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol (1999) 1.06
Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J Neuroimmunol (1996) 1.06
Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience (2008) 1.05
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages. J Leukoc Biol (1998) 1.04
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression. J Immunol (1999) 1.02
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J Biol Chem (2001) 1.02
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo. J Immunol (2001) 1.02
In vitro stimulatory effect of substance P on hematopoiesis. Blood (1993) 1.01
Inhibition of IFN-gamma-induced janus kinase-1-STAT1 activation in macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Immunol (2000) 1.00
ELISA in the Q fever diagnosis. Arch Roum Pathol Exp Microbiol (1984) 0.98
Expression of caveolae on the surface of rat arterial smooth muscle cells is dependent on the phenotypic state of the cells. Lab Invest (1997) 0.95
Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP. Ann N Y Acad Sci (2000) 0.94
Transcription termination within the Escherichia coli origin of DNA replication, oriC. Mol Gen Genet (1986) 0.94
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem (1999) 0.91
Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase, and transcription factors NFkappaB and AP-1. Cardiovasc Res (2000) 0.91
Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. J Immunol (1993) 0.89
An alpha2-macroglobulin associated factor produced by T lymphocytes which provides polyclonal stimulation of B lymphocytes to maintain the turnover of their surface Ig. Immunology (1981) 0.89
Dpp and Hh signaling in the Drosophila embryonic eye field. Development (2001) 0.89
VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies. J Neuroimmunol (1998) 0.88
Glucocorticoid pretreatment protects cardiac function and induces cardiac heat shock protein 72. Am J Physiol Heart Circ Physiol (2000) 0.87
Inhibition of endotoxin-induced macrophage chemokine production by VIP and PACAP in vitro and in vivo. Arch Physiol Biochem (2001) 0.87
VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression. Ann N Y Acad Sci (2000) 0.86
Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol (1997) 0.86
Vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in LPS-stimulated macrophages. J Neuroimmunol (2000) 0.85
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit antigen-induced apoptosis of mature T lymphocytes by inhibiting Fas ligand expression. J Immunol (2000) 0.85
Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex. J Neuroimmunol (1993) 0.84
Induction of IL-3 and granulocyte-macrophage colony-stimulating factor by substance P in bone marrow cells is partially mediated through the release of IL-1 and IL-6. J Immunol (1994) 0.84
Murine T-lymphocytes express vasoactive intestinal peptide receptor 1 (VIP-R1) mRNA. J Neuroimmunol (1996) 0.84
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide-38 inhibit IL-10 production in murine T lymphocytes. J Immunol (1996) 0.84
Degradation of a chromogenic substrate by alpha 2-macroglobulin from plasma of patients with rheumatoid arthritis. Arthritis Rheum (1984) 0.84
Effect of serum alpha2-macroglobulin on the trypsin-soybean trypsin inhibitor complex. Arch Roum Pathol Exp Microbiol (1975) 0.84
VIP and PACAP inhibit activation induced apoptosis in T lymphocytes. Ann N Y Acad Sci (2000) 0.84
VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression. J Immunol (1999) 0.83
Pretreatment with methylprednisolone protects the isolated rat heart against ischaemic and oxidative damage. Free Radic Res (2000) 0.83
Effect of vasoactive intestinal peptide (VIP) on cytokine production and expression of VIP receptors in thymocyte subsets. Regul Pept (1997) 0.83
The neuropeptides VIP and PACAP inhibit IL-2 transcription by decreasing c-Jun and increasing JunB expression in T cells. J Neuroimmunol (2000) 0.83
Polyclonal B-cell activator with esterolytic activity and polyclonal gammopathy induced by allogeneic cells in rabbits. Immunology (1982) 0.83
Extrachromosomal eukaryotic DNA substrates for switch recombination: analysis of isotype and cell specificity. DNA Cell Biol (1994) 0.83
Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide. J Neuroimmunol (1999) 0.82
VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann N Y Acad Sci (1999) 0.82
Role of tyrosine kinases in extracellular matrix-mediated modulation of arterial smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol (1997) 0.82
Species-specific activity of rat recombinant interleukin-1 beta. J Interferon Cytokine Res (1995) 0.81
Immunoregulatory effects of neuropeptides. Stimulation of interleukin-2 production by substance p. J Neuroimmunol (1992) 0.81
TH2 lymphocytes secrete functional VIP upon antigen stimulation. Arch Physiol Biochem (2001) 0.81
Blast transformation of B cells induced by an alpha-macroglobulin-associated lymphokine produced in crowded lymphoid cell cultures. J Immunol (1983) 0.81
Neuroprotective and consequent neurorehabilitative clinical outcomes, in patients treated with the pleiotropic drug cerebrolysin. J Med Life (2010) 0.80
Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production in murine thymocytes activated via the TCR/CD3 complex. J Neuroimmunol (1994) 0.80
VIP and PACAP enhance the in vivo generation of memory TH2 cells by inhibiting peripheral deletion of antigen-specific effectors. Arch Physiol Biochem (2001) 0.80
The effect of protease inhibitors on the polyclonal B cell activator from the serum of patients with rheumatoid arthritis. Int J Immunopharmacol (1982) 0.79
VIP and PACAP inhibit Fas ligand-mediated bystander lysis by CD4(+) T cells. J Neuroimmunol (2001) 0.79
Effects of calcium blockers on the cytosolic calcium, H2O2 production and elastase release in human neutrophils. Pharmacol Toxicol (1996) 0.79
Introduction to the study of adult T-cell leukemia and HTLV-I sero-positivity in Romania. Rom J Intern Med (1994) 0.79
VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann N Y Acad Sci (1998) 0.78
Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia. Ann N Y Acad Sci (2000) 0.78
Down-regulation of cytokine expression in murine lymphocytes by PACAP and VIP. Ann N Y Acad Sci (1996) 0.78
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression. J Immunol (2000) 0.78
Levels of alpha-fetoprotein and alpha2-macroglobulin in humours of mice of various ages. Arch Roum Pathol Exp Microbiol (1976) 0.77
The protective activity of murine and human alpha 2-macroglobulin on the lethally irradiated mice. Arch Roum Pathol Exp Microbiol (1980) 0.77
Allogeneic lymphocyte stimulation in rabbits: induction of a low MW inhibitor for trypsin and for a concurrently induced alpha-macroglobulin-proteinase complex. Immunology (1985) 0.76
The effect of alpha-fetoprotein on the immune response. III. Diminution of the phagocytic capacity of macrophages cultures in vitro in the presence of mouse amniotic fluid or alpha-fetorprotein. Arch Roum Pathol Exp Microbiol (1978) 0.76
Neuropeptide regulation of cytokine expression: effects of VIP and Ro 25-1553. J Interferon Cytokine Res (1995) 0.76
A low molecular weight proteinase inhibitor produced by T lymphocytes. Immunology (1986) 0.76
Expression of NK-1 receptor mRNA in murine T lymphocytes. Neuroimmunomodulation (1997) 0.76
Vasoactive intestinal peptide (VIP) inhibits TGF-beta1 production in murine macrophages. J Neuroimmunol (2000) 0.76
Vasoactive intestinal peptide inhibits cytokine production in T lymphocytes through cAMP-dependent and cAMP-independent mechanisms. Regul Pept (1999) 0.75
[Epizootiology of foot-and-mouth disease in Rumania and its influence on methods of prevention]. Bull Off Int Epizoot (1973) 0.75
[Effects of neuroleptanalgesia during labor on the fetal heart and on uterine contractions]. Bull Fed Soc Gynecol Obstet Lang Fr (1968) 0.75
[The autoimmune component in periodontal diseases in patients with thyroid dysfunction]. Rev Med Chir Soc Med Nat Iasi (1978) 0.75
[Monitoring central venous pressure in post abortum endotoxic shock]. Obstet Ginecol (Bucur) (1975) 0.75
[Sequels of viral hepatitis and factors in chronicization of it (a clinico-epidemiological study)]. Med Interna (Bucur) (1968) 0.75
[Oto-neuropsychiatric aspects of the child with a hearing deficit. Differential diagnosis and medico-pedagogical trends]. Otorinolaringologie (1966) 0.75
[Dyshormonism of the adrenal glands in gastroduodenal ulcer]. Rev Med Chir Soc Med Nat Iasi (1969) 0.75
[On the interrelations between chronic hepatopathies and diabetes mellitus]. Med Interna (Bucur) (1971) 0.75
[Considerations on a pneumopathy appearing in a case of ankylosing spondylitis]. Med Interna (Bucur) (1966) 0.75
[Cesarean operations under neuroleptanalgesia]. Bull Fed Soc Gynecol Obstet Lang Fr (1968) 0.75
[Pathogenic considerations on the jejunal syndrome in gastrectomized patients. Therapeutic deductions]. Med Interna (Bucur) (1970) 0.75
[Tracheobronchial carcinoids]. Rev Chir Oncol Radiol O R L Oftalmol Stomatol Chir (1977) 0.75
[Value of adrenal antibodies for the etiological diagnosis of chronic adrenal insufficiency]. Rev Med Chir Soc Med Nat Iasi (1975) 0.75
[Scientific principles of the prevention of foot-and-mouth disease]. Veterinariia (1973) 0.75
[The prevention of aphthous fever in Rumania during the past 4 years]. Bull Off Int Epizoot (1971) 0.75
[Pericardomyocardial metastasis secondary to a renal carcinoma with cardiac insufficiency abated by treatment]. Med Interna (Bucur) (1965) 0.75
[Duration of post-vaccination immunity against foot-and-mouth disease in relation to animal age, vaccine dose and vaccination repetition (recurrence effect)]. Bull Off Int Epizoot (1973) 0.75
Cytokines in NZB CD5+ B clones. Ann N Y Acad Sci (1992) 0.75
[Arterial oxygen desaturation in chronic liver diseases and its effects on the central nervous system]. Med Interna (Bucur) (1967) 0.75
Histochemistry of the epimerases 3. Uridine diphosphogalactose-4-epimerase. Histochemie (1968) 0.75
[Influencing of the maternal and fetal acid-base equilibrium through labor under analgesia]. Arch Gynakol (1971) 0.75